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Objective: This retrospective study aimed to determine the predictive factors for the efﬁcacy of pelvic
arterial embolization for postpartum hemorrhage.
Materials and methods: Twenty-one patients who underwent pelvic arterial embolization for postpartum
hemorrhage of >1000 mL between September 2006 and September 2011 were enrolled in this study. The
patients were divided into two subgroups according to the blood loss and time from the end of pelvic
arterial embolization to complete hemostasis: good-response (16 patients) and poor-response groups (5
patients). The following predictive factors were compared between the groups: (1) patient character-
istics; (2) blood loss; (3) time between delivery (or onset of bleeding) and pelvic arterial embolization;
(4) obstetrical disseminated intravascular coagulation score comprising clinical background, clinical
signs, and laboratory data; (5) individual disseminated intravascular coagulation score; (6) shock index;
and (7) laboratory data including platelet count, prothrombin time-international normalized ratio,
ﬁbrinogen, ﬁbrin degradation products, and antithrombin-III at the time of pelvic arterial embolization.
Results: In the poor-response group, the obstetrical and individual disseminated intravascular coagula-
tion scores and prothrombin time-international normalized ratio were higher than those in the good-
response group (p < 0.05). Platelet count, ﬁbrinogen, and ﬁbrin degradation products were lower than
those in the good-response group (p < 0.05). All obstetrical disseminated intravascular coagulation scores
in the poor-response group were >9 points.
Conclusion: The efﬁcacy of pelvic arterial embolization is related to the presence or absence of coagu-
lation disorders. When the obstetrical disseminated intravascular coagulation score is high (>9 points),
the efﬁcacy may be poor.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Postpartum hemorrhage (PPH) is still one of the leading causes
of maternal death in developed countries [13]. Over the past few
decades, pelvic arterial embolization (PAE) has become a reliabletal, and Neonatal Medicine,
nan-ku, Fukuoka 814-0180,
oshizato).
bstetrics & Gynecology. Publishedand safe alternative treatment method for PPH when uncontrolla-
ble hemorrhage occurs with conventional procedures such as
manual and surgical compression of the uterus, local and systemic
administration of uterotonic agents, and suturing of bleeding sites
of the uterus and birth canal [46]. The success rate of PAE for PPH
is high (79e95%) with complications rates from 3% to 12% [79].
PAE has an advantage over ligation of hypogastric and uterine ar-
teries and hysterectomy for a variety of reasons. PAE can possibly
control hemorrhage in regions that are not supplied by surgically
ligated arteries or sites in which collateral circulation exists. Thisby Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient characteristics.
Case Age (y) Parity Medical
complications
Obstetric complications GA at delivery
(wk/d)
Mode of delivery Causes of PPH
1 36 2 e Abruptio placentae 39/3 Transvaginal Uterine atony
2 34 1 e Abruptio placentae, IUFD 35/3 Hysterectomy Uterine atony
3 31 0 e Preeclampsia, LLP 37/2 Emergency CS Uterine atony
4 35 3 e Placenta previa 36/1 Elective CS Uterine atony
5 25 1 MCTD Abruptio placentae, IUFD 28/5 Hysterectomy Coagulopathy
6 29 1 e e 32/6 Emergency CS Uterine atony
7 37 1 e e 37/0 Elective CS Placenta accreta
8 36 2 e e 37/0 Elective CS Uterine atony
9 29 1 Focal
glomerulonephritis
e 34/5 Elective CS Uterine atony
10 39 1 e e 41/2 Transvaginal Uterine atony
11 25 0 e e 40/6 Transvaginal Retained placenta
12 32 0 e e 40/2 Transvaginal Uterine atony
13 27 2 e Gestational hypertension 37/4 Transvaginal Uterine atony
14 29 1 e e 40/4 Transvaginal Uterine atony
15 34 2 e e 38/1 Elective CS Pseudo-aneurysm
16 31 0 e Preeclampsia 40/5 Transvaginal Uterine atony
17 37 2 e e 39/2 Transvaginal Undetermined
18 31 2 e e 39/5 Transvaginal Pseudo-aneurysm
19 37 3 e e 39/4 Transvaginal Retained placenta
20 33 2 e e 40/0 Transvaginal Undetermined
21 31 1 e e 40/4 Transvaginal Undetermined
CS ¼ Cesarean section; GA ¼ gestational age; IUFD ¼ intrauterine fetal death; LLP ¼ low-lying placenta; MCTD ¼ mixed connective tissue disease; PPH ¼ postpartum
hemorrhage.
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whom surgical interventions are contraindicated. Furthermore, it
preserves the reproductive function of patients, including the
ability to become pregnant in the future.
When treating patients with PPH, it is vital to know the efﬁcacy
of PAE in advance to determine the best strategy with which to
control hemorrhage that is refractory to conventional procedures.
Which patients are good candidates for PAE and under which
conditions is it appropriate to intervene? To the best of our
knowledge, there have been three reports regarding the predictive
factors of PAE for PPH; however, the criteria for success of PAE andTable 2
DIC scoring.
(1) Clinical background Points (2) Clinical signs
a. Abruptio placenta a. Acute renal failure
Uterine hypertonicity, dead fetus 5 Anuria (5 mL/h)
Uterine hypertonicity, live fetus 4 Oliguria (>5 and 20 mL/h)
Abnormal CTG/ultrasound
ﬁndings suggestive of abruption
4 b. Acute respiratory failure (e
amniotic ﬂuid embolism)
b. Amniotic ﬂuid embolism On full mechanical ventilation
occasionally on assisted ventila
With acute cor pulmonale 4 On oxygen mask
On full mechanical ventilation 3 c. Severe organ damage to he
central nervous system, or
gastrointestinal tract
On assisted ventilation 2 Heart (rales, foamy sputum, etc
On oxygen mask 1 Liver (recognizable jaundice)
c. Postpartum hemorrhage CNS (unconsciousness, convuls
Sampled blood or blood from
birth canal, uncoagulated
or hypocoagulated
4 Gastrointestinal tract (necrotiz
enterocolitis)
Blood loss of 2000 mL (24 h) 3 d. Bleeding tendency
Blood loss of 1000
and <2000 mL (24 h)
1 Macroscopic hematuria, melen
or bleeding from mucosa, ging
where needle is inserted
d. Eclampsia e. Shock state
Eclampsia 4 Pulse 100/min
e. Others (leading to DIC) 1 Systolic blood pressure 90 m
or 40% of baseline
Sweating
Paleness
a2-PI ¼ a2-plasminogen inhibitor; AT-III ¼ anti-thrombin-III; CNS ¼ central nervous
FDP ¼ ﬁbrin degradation products.the indications for repeat PAEwere ill-deﬁned [7,8,10]. In this study,
patients with PPH who underwent PAE in our three institutes were
retrospectively reviewed. Based on well-deﬁned criteria for he-
mostasis after PAE, the aimwas to determine the predictive factors
for the efﬁcacy of PAE.
Materials and methods
Between September 2006 and September 2011, a total of 6772
births were recorded at Fukuoka University Hospital, Fukuoka
Tokushukai Hospital, and Yamaguchi Red Cross Hospital, Fukuoka,Points (3) Laboratory data Points
FDP 10 mg/mL 1
4 Platelet count 100,000/mL 1
3 Fibrinogen 150 mg/dL 1
xcluding Prothrombin time 15 s (50%)
or hepaplastin test 50%
1
or
tion
4 Erythrocyte sedimentation
rate 4 mm/15 min or 15 mm/h
1
1 Bleeding time >5 min 1
art, liver, Abnormal values of the other
biomarkers for coagulation,
ﬁbrinolysis, and kinin
1
.) 4 (e.g., AT-III 18 mg/dL or 60%,
or prekallikrein, a2-PI, plasminogen,
or other coagulation factors 50%)
4
ion, etc.) 4
ing 4
a, purpura,
iva, or sites
4
1
mHg 1
1
1
system; CTG ¼ cardiotocogram; DIC ¼ disseminated intravascular coagulation;
Table 3
PAE methods and ﬁndings during pelvic arterial embolization in the individual cases.
Case Time for PAE (min) Embolized vessels Embolization material Extravasation
1 75 Uterine arteries, bilateral Absorbable gelatin sponge, coil 
2 95 Uterine artery, right Absorbable gelatin sponge þ
3 110 Internal iliac arteries, bilateral Absorbable gelatin sponge 
4 62 Uterine arteries, upper branch, bilateral Absorbable gelatin sponge þ
44 Uterine arteries, upper branch, bilateral Absorbable gelatin sponge 
5 40 Uterine artery, cervicovaginal branch, left Absorbable gelatin sponge, coil þ
6 65 Uterine arteries, bilateral Absorbable gelatin sponge, coil þ
7 130 Uterine arteries, upper branch, bilateral Absorbable gelatin sponge 
8 92 Uterine arteries, upper branch, bilateral Absorbable gelatin sponge 
9 220 Uterine arteries, bilateral Absorbable gelatin sponge 
10 55 Uterine arteries, bilateral Absorbable gelatin sponge 
11 111 Uterine arteries, upper branch, bilateral Absorbable gelatin sponge þ
12 60 Uterine arteries, upper branch bilateral Absorbable gelatin sponge 
13 59 Uterine arteries, bilateral Absorbable gelatin sponge 
14 80 Uterine arteries, bilateral Absorbable gelatin sponge 
15 60 Uterine artery, left Absorbable gelatin sponge þ
16 40 Uterine arteries, upper branch, bilateral Absorbable gelatin sponge 
17 80 Uterine arteries, bilateral Absorbable gelatin sponge 
18 60 Uterine arteries, upper branch, bilateral Absorbable gelatin sponge 
19 100 Uterine arteries, bilateral Absorbable gelatin sponge 
20 85 Uterine arteries, bilateral Absorbable gelatin sponge 
21 75 Uterine arteries, bilateral Absorbable gelatin sponge, coil þ
PAE ¼ pelvic arterial embolization.
Fig. 1. Blood loss and time interval in hours from the end of pelvic arterial emboli-
zation to complete hemostasis in the individual cases. Complete hemostasis was
deﬁned as blood loss of <10 mL per hour. Numbers indicate the case numbers as
shown in Table 1. Good ¼ good-response group; Poor ¼ poor-response group. In Case 4,
the blood loss and time interval was calculated from the ﬁrst embolization.
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during this period, 23 underwent PAE for PPH. After excluding two
patients for whom complete medical records were not obtained, 21
patients were subjected to subsequent analysis. This study was
approved by the institutional review boards of the individual
hospitals.
The patients' characteristics are summarized in Table 1. The
median maternal age was 32.0 years (range, 25e39 years). Four
patients were primiparous. Two patients had medical complica-
tions: one had mixed connective tissue disease, and one had focal
glomerulonephritis. Seven patients had obstetrical complications:
three had abruptio placentae, one had preeclampsia, one had pre-
eclampsia and a low-lying placenta, one had gestational hyper-
tension, and one had placenta previa. Themedian gestational age at
delivery was 39.0 (range, 28e41) weeks. Twelve patients delivered
transvaginally, and the remaining nine patients underwent Cesar-
ean section or hysterectomy. The causes of PPH included 12 cases of
uterine atony, two cases of retained placenta, two cases of rupture
of a pseudoaneurysm of the uterus or birth canal, one case of
placenta accreta, one case of coagulopathy, and three cases of un-
known cause. Eleven patients were referred from other hospitals
for the treatment of PPH.
The policy for the treatment of PPH refractory to conventional
procedures is that PAE is the ﬁrst-choice therapy unless the hemo-
dynamic state of the patient is critically unstable. No patients un-
derwent ligation of the hypogastric and/or uterine arteries or
hysterectomy prior to considering PAE. Supportive therapies for
blood loss and treatment for coagulopathy were performed when
necessary prior to, during, and after PAE. Twenty patients had a
blood transfusion as indicated by the guidelines proposed by the
Japan Society of Obstetrics and Gynecology [11]. Treatment for
disseminated intravascular coagulation (DIC) was started when the
total obstetrical DIC score, originally proposed by Maki et al [12]
(Table 2), was 8 points. PAE was performed in 16 patients for pri-
mary PPH occurring within the ﬁrst 24 hours after delivery and in
the remaining ﬁve patients for secondary PPH that occurred
>24 hours but <6 weeks from delivery. PAE was performed by
well-trained interventional radiologists. The PAE methods were
chosen on a case-by-case basis and are summarized in Table 3.
The median time for PAE was 75 (range, 40e220) minutes. Extrav-
asation occurred in sevenpatients. The internal iliac arteries, uterinearteries, or peripheral branches of the uterine arteries were
embolized unilaterally in three patients and bilaterally in 18 pa-
tients. Regarding the embolization agents, absorbable gelatin
sponges were used in 17 patients, and absorbable gelatin sponges
andplatinumcoilswereused in four patients. Onlyonepatient (Case
4) underwent repeat PAE.
The efﬁcacy of PAE was evaluated according to the blood loss
and time interval in hours from the end of PAE to complete he-
mostasis. Complete hemostasis was deﬁned as blood loss of <10mL
per hour. The patients were divided into two subgroups: the good-
response group (16 patients) and poor-response group (ﬁve pa-
tients). In the former group, the blood loss was 0240 mL (median,
8 mL), and the time interval until complete hemostasis was 16
hours (median, 1.5 hours). In the latter group, the blood loss was
5132430 mL (median, 1053 mL), and the time interval until
complete hemostasis was 918 hours (median, 9.0 hours; Fig. 1).
The following predictive factors related to the efﬁcacy of PAE for
PPH between the good- and poor-response groups were compared:
Fig. 2. Blood loss and time interval between delivery (or onset of bleeding) and pelvic arterial embolization in the good- and poor-response groups. Bars indicate medians of
individual groups. PAE ¼ pelvic arterial embolization; Good ¼ good-response group; Poor ¼ poor response group.
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and obstetrical complications, gestational age at delivery, and de-
liverymode; (2) blood loss; (3) time interval from delivery (or onset
of bleeding for secondary PPH) to PAE; (4) shock index (SI; i.e., pulse
rate divided by systolic blood pressure); (5) total and individual
obstetrical DIC scores; and (6) laboratory data as mentioned below
regarding coagulation and ﬁbrinolysis at PAE or the most recent
time prior to PAE. The total obstetrical DIC score comprised the
three individual scorings representing the clinical background,
clinical signs, and laboratory data regarding coagulation and ﬁbri-
nolysis. The laboratory data included platelet count, prothrombin
time-international normalized ratio (PT-INR), ﬁbrinogen, ﬁbrin
degradation products (FDP), and anti-thrombin-III (AT-III). When
the data were beyond or less than the detection limits, these limits
were indicated as the representative values.
The statistical analyses were performed using the Chi-square
test and MannWhitney test, and statistical signiﬁcance was set
at p < 0.05.Table 4
Parameters before pelvic arterial embolization in the individual cases.
Case Blood loss
from deliverya
to PAE (mL)
Time interval
from deliverya
to PAE (h)
Shock index
at PAE
DIC score at PAE (points)
Total Clinical
background
Clin
sign
1 5400 4 1.5 21 4 12
2 2770 4 1.2 13 5 3
3 3390 11 0.9 12 3 4
4 1740 4 1.8 11 3 4
5 2458 4 0.6 10 5 1
6 4650 2 0.8 10 3 2
7 5900 6 1.2 9 3 3
8 3776 6 1.0 8 3 1
9 1885 5 0.8 8 1 4
10 3482 5 1.0 7 3 2
11 3073 5 0.6 7 3 3
12 3000 9 1.4 7 3 2
13 1791 8 0.8 7 1 3
14 4150 6 2.1 6 3 1
15 1028 5 0.8 5 1 1
16 2123 10 0.7 4 3 1
17 1766 7 1.0 4 1 1
18 1620 14 0.5 4 1 1
19 1570 3 0.9 4 1 1
20 1364 8 0.7 2 1 1
21 1460 5 0.7 1 1 0
AT-III ¼ antithrombin-III; FDP ¼ ﬁbrin degradation products; PAE ¼ pelvic arterial embo
a Onset of bleeding in patients who experienced secondary postpartum hemorrhage.Results
There were no differences in maternal age, parity, gestational
age at delivery, or rate of Cesarean section between the groups.
There was one patient with mixed connective disease in the poor-
response group and one patient with focal glomerulonephritis in
the good-response group (Table 1). All ﬁve patients in the poor-
response group had obstetrical complications: abruptio placentae
(3 patients), placenta previa (1 patient), and low-lying placenta and
preeclampsia (1 patient). By contrast, among the patients in the
good-response group, only two had obstetrical complications:
gestational hypertension (1 patient) and preeclampsia (1 patient).
There was no difference in the blood loss prior to PAE in the
good- versus poor-response groups (2665 ± 1400 mL vs.
3152 ± 1390 mL, respectively), the time interval from delivery (or
onset of bleeding) to PAE (6.5 ± 2.9 hours vs. 5.4 ± 3.1 hours,
respectively; Fig. 2, Table 4), and the shock index at PAE (0.9 ± 0.4
vs. 1.2 ± 0.5, respectively; Fig. 3, Table 4).Laboratory data at PAE
ical
s
Lab
data
Platelets
(  103/mL)
PT (s or %)
(PT-INR)
Fibrinogen
(mg/dL)
FDP
(mg/mL)
AT-III (%)
5 58 >80.0 (>8.53) <50 >120 25
5 44 19.4 (1.62) 63 88 44
5 54 32% (2.14) <50 >120 19
4 108 15.5 (1.38) 104 >120 >130
4 62 15.5 (1.33) 52 57 51
5 95 19.1 (1.69) 68 113 32
3 132 17.4 (1.51) 55 >120 48
4 47 14.4 (1.21) 125 42 58
3 130 18.4 (1.67) <50 >120 72
2 115 12.8 (1.27) 159 15 49
1 217 13.5 (1.15) 217 11 52
2 151 15.8 (1.36) 249 8 55
3 146 15.1 (1.23) 132 <5 41
2 84 75% (1.20) 157 65 86
3 123 17.4 (1.58) <50 >120 66
0 128 12.6 (1.07) 202 9 63
2 303 83% (1.12) 188 16 60
2 235 13.3 (1.21) 82 84 106
2 180 13.8 (1.22) 132 40 69
0 244 93% (1.05) 207 5 82
0 263 78% (1.16) 168 8 88
lization; PT (INR) ¼ prothrombin time (international normalized ratio).
Fig. 3. Shock indices prior to pelvic arterial embolization in the good- and poor-
response groups. Bars indicate medians of individual groups. Good ¼ good-response
group; Poor ¼ poor response group.
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response group were higher than those of the patients in the
good-response group (p ¼ 0.001; Fig. 4). All patients in the poor-
response group had total obstetrical DIC scores of >9 points. The
obstetrical DIC scores for clinical background, clinical signs, and
laboratory data of the patients in the poor-response group were
higher than those of the patients in the good-response group
(p ¼ 0.004, p ¼ 0.027, and p ¼ 0.003, respectively).
The platelet count and ﬁbrinogen level of the patients in the
poor-response group were lower than those of the patients in the
good-response group (p¼ 0.005 and p¼ 0.020, respectively; Fig. 5).
The PT-INR and FDP concentration of the patients in the poor-
response group were higher than those of the patients in the
good-response group (p ¼ 0.017 and p ¼ 0.033, respectively). There
was no difference in the AT-III activity between the groups.
Discussion
PPH refractory to conventional procedures was well controlled
by PAE alone, with a single PAE success rate of 95.2% and a second-Fig. 4. Obstetrical DIC scores of total, clinical background, clinical signs, and laboratory d
indicate medians of individual groups. DIC ¼ disseminated intravascular coagulation; Goodattempt PAE success rate of 4.8%; these outcomes are similar to
those previously reported [7,9,13]. In this study, the efﬁcacy of PAE
for PPH was evaluated by the blood loss and time interval from the
end of PAE to complete hemostasis, and the patients were clearly
divided into good- and poor-response groups. The only predictive
factor for the efﬁcacy of PAE was the presence or absence of coa-
gulopathy; i.e., high obstetrical DIC scores and abnormal levels of
biomarkers including platelet count, PT-INR, ﬁbrinogen, and FDP.
All ﬁve patients in the poor-response group had either placental
abruption or abnormal placentation, which are associated with a
high risk of inducing coagulopathy.
There have been three reports concerning the predictive factors
for PAE failure or the requirement for repeat PAE within 24 hours
after the ﬁrst PAE [7,8,10]. The risk factors were being primiparous,
the presence of a coagulation disorder, extravasation, and an
anatomical variant of the uterine arterial vasculature. Our results
were partially compatible with these results. In this study, it was
aimed to determine the predictive factors prior to PAE, and the
factors thatwere obtainedduring PAEwere excluded. Therewere no
differences in terms of extravasation between the poor- and good-
response groups [40.0% (2/5) vs. 31.3% (5/16), respectively]. No pa-
tients showed any anatomical variants of the uterine vasculature.
The remaining problems concern how to treat patients with a
poor response to improve the efﬁcacy of PAE. There were no dif-
ferences in blood loss and time interval from delivery (or onset of
bleeding) to PAE between the groups. However, in Case 3, which
was referred from another hospital, 11 hours were required before
PAE could deteriorate the coagulopathy; this case may have had a
better outcome if the patient had been transferred in a timely
manner and PAE had been performed earlier. When timely PAE is
not available, prompt correction of any coagulopathies is necessary
prior to PAE. The PAE procedures were performed at the discretion
of each interventional radiologist. Two of the ﬁve patients in the
poor-response group developed extravasation (Cases 2 and 5); only
the ipsilateral artery was embolized. Complete hemostasis was
conﬁrmed during PAE; however, the collateral circulation from the
contralateral or ovarian arteries may play a role in the development
of hemorrhage after PAE. Another factor to be considered is the
indication for repeat PAE. There was no clear criteria for repeat PAE.
A second PAEwas performed in Case 4 because substantial bleeding
continued after the ﬁrst PAE. Some authors recommend that repeat
PAE is effective for uncontrollable bleeding after the ﬁrst PAE priorata prior to pelvic arterial embolization in the good- and poor-response groups. Bars
¼ good-response group; Poor ¼ poor response group.
Fig. 5. Laboratory data before pelvic arterial embolization in the good- and poor-response groups. Bars indicate medians of individual groups. AT-III ¼ anti-thrombin-III;
FDP ¼ ﬁbrin degradation products; Good ¼ good-response group; Poor ¼ poor response group; PT-INR ¼ prothrombin time-international normalized ratio.
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repeat PAE, more intensive embolization may be necessary, which
may lead to profound tissue damage later [14]. In fact, in Case 4, a
hysterectomy was performed 82 days after PAE because of massive
necrosis of the myometrial tissues. The balance between hemo-
stasis by repeat PAE and potential complications should be
considered, and this issue will be clariﬁed in a further study.
Limitations of this study are its retrospective nature and inclu-
sion of a small number of patients, yielding low statistical power. In
addition, the results were biased because the clinical backgrounds
and indications for PAE in this study differ from those of other re-
ports. However, the results conﬁrm that PAE is a safe alternative
method to current surgical procedures for uncontrollable post-
partum bleeding if the candidate is carefully chosen. These ﬁndings
will provide informative feedback to obstetricians who plan to
implement this technique in their clinical setting.Conﬂicts of interest
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